^
Association details:
| Biomarker: | BCL2 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | barasertib-HQPA (AZD2811) (Aurora kinase B inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ACTIVITY OF THE NOVEL AURORA KINASE B INHIBITOR AZD2811 IN BIOMARKER-DEFINED MODELS OF SMALL CELL LUNG CANCER
Published date:
09/28/2019
Excerpt:
cMYC (Fold change, FC:2.5; P = 0.015) and Vimentin (FC:1.66; P = 0.022) were top biomarkers of sensitivity, while high E-cadherin (FC:1.94; P = 0.046) and BCL-2 (FC:1.86; P = 0.032) associated with resistance. Interestingly....The high BCL2 levels observed in resistant cells provide a rationale for exploring AURKB/BCL2-i combinations.
DOI:
10.1093/annonc/mdz264
